基于网络药理学和分子对接探讨抵挡汤抗肺纤维化作用机制研究
Study on Anti-Pulmonary Fibrosis Mechanism of Didang Decoction Based on Network Pharmacology and Molecular Docking
DOI: 10.12677/TCM.2023.127276, PDF,    国家自然科学基金支持
作者: 杨其芬*, 赵惠亮, 陈 隆, 渠景连#:贵州中医药大学基础医学院,贵州 贵阳
关键词: 肺纤维化网络药理分子对接抵挡汤Pulmonary Fibrosis Network Pharmacology Molecular Docking Didang Decoction
摘要: 抵挡汤具有治疗肺部纤维化的作用,但其作用机制尚不明确,本文基于网络药理学和分子对接探讨抵挡汤抗肺纤维化的作用机制。运用TCMSP数据库和BATMAN数据库筛选出抵挡汤的活性成分和靶点,在GeneCards、OMIM、TTD数据库中获得疾病相关靶点,通过Venny 2.1在线平台制作Venny图获得抵挡汤与肺纤维化的交集靶点,再利用Cytoscape软件构建药物–活性化合物–靶点网络,String数据库构建 PPI网络,利用Metascape数据库对交集靶点进行富集分析,最后选取关键靶点对抵挡汤的关键成分进行分子对接验证。研究得到抵挡汤活性成分60个,交集基因共有454个,蛋白互作分析得到核心作用靶点有AKT1、EP300、SRC等,GO分析富集显示相关生物过程涉及基因表达的正向调控、对药物反应、对RNA聚合酶II启动子转录的正向调控等,KEGG富集结果显示主要通路涉及癌症通路、AGE-RAGE信号通路、人巨细胞病毒感染等。研究结果表明抵挡汤抗肺纤维化具有多成分、多靶点、多通路协同调节的特点,为其后期作用机制研究奠定了基础。
Abstract: Didang Decoction has the effect of treating pulmonary fibrosis, but its mechanism of action is not clear. Based on network pharmacology and molecular docking, this paper discusses the mechanism of Didang Decoction against pulmonary fibrosis. The active ingredients and targets of antisepsis decoction were screened using TCMSP and BATMAN databases, disease-related targets were obtained from GeneCards, OMIM and TTD databases, and the intersection targets of antisepsis decoction and pulmonary fibrosis were obtained by making Venny diagram through Venny 2.1 online platform. Cytoscape software was used to construct a drug-active compound-target network, String database was used to construct a PPI network, Metascape database was used for enrichment analysis of intersection targets, and finally, key targets were selected for molecular docking verification.60 active components of the decoction were obtained, including 454 overlapping genes. Protein interaction analysis showed that the core targets were AKT1, EP300, SRC, etc. GO analysis enrichment showed that the related biological processes involved positive regulation of gene expression, drug response, and RNA polymerase II promoter transcription. KEGG enrichment results showed that the major pathways involved the cancer pathway, AGE-RAGE signaling pathway and human cytomegalovirus infection. The results showed that Didang Decoction has the characteristics of multi-component, multi-target and multi-pathway synergistic regulation, which laid the foundation for the later study of its mechanism of action.
文章引用:杨其芬, 赵惠亮, 陈隆, 渠景连. 基于网络药理学和分子对接探讨抵挡汤抗肺纤维化作用机制研究[J]. 中医学, 2023, 12(7): 1854-1866. https://doi.org/10.12677/TCM.2023.127276

参考文献

[1] Kinoshita, T. and Goto, T. (2019) Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review. International Journal of Molecular Sciences, 20, Article 1461. [Google Scholar] [CrossRef] [PubMed]
[2] Wu, Q., Zhang, K.J., Jiang, S.M., et al. (2020) p53: A Key Protein That Regulates Pulmonary Fibrosis. Oxidative Medicine and Cellular Longevity, 2020, Article 6635794. [Google Scholar] [CrossRef] [PubMed]
[3] 钟昌会, 冼丽娜, 钱进, 等. 肺纤方通过调控HMGB1/TLR2信号通路抑制特发性肺纤维化的实验研究[J]. 中华中医药学刊, 2023, 41(4): 55-59+263.
[4] 雷凯春. 吡非尼酮治疗特发性肺纤维化的临床疗效及不良反应[D]: [硕士学位论文]. 兰州: 兰州大学, 2018.
[5] 渠景连. 养肺通络法干预Notch信号通路防治肺纤维化的机制研究[D]: [博士学位论文]. 南京: 南京中医药大学, 2015.
[6] 乔虎, 全立欣, 付子佳, 等. 从肺损络伤探讨特发性肺纤维化的发病机制与治疗[J]. 中医药学报, 2023, 51(3): 48-50.
[7] 吴希泽, 康健, 李越, 等. 抵挡汤的研究进展[J/OL]. 中国实验方剂学杂志, 2023: 1-10. , 2023-07-28.[CrossRef
[8] 林庶茹, 才丽平. 抵当汤合小陷胸汤化裁方对实验性肺间质纤维化大鼠血清透明质酸与Ⅳ型胶原的影响[J]. 中国中医基础医学杂志, 2005, 11(12): 897-898.
[9] Hewlett, J.C., Kropski, J.A. and Blackwell, T.S. (2018) Idiopathic Pulmonary Fibrosis: Epitheli-al-Mesenchymal Interactions and Emerging Therapeutic Targets. Matrix Biology, 71-72, 112-127. [Google Scholar] [CrossRef] [PubMed]
[10] 王学. BALF中CCL2、ECM1水平对特发性肺纤维化患者预后的判断价值[D]: [硕士学位论文]. 南京: 南京中医药大学, 2022.
[11] 丛晓东, 曹庆, 何沂, 等. 新型冠状病毒肺炎恢复期肺纤维化的治疗思路与方法[J]. 中医学报, 2020, 35(8): 1583-1586.
[12] 张广成, 吕勇. 中药防治肾小球硬化研究进展[J]. 实用中医药杂志, 2015, 31(1): 73-74.
[13] Xia, Q.D., Xun, Y., Lu, J.L., et al. (2020) Network Pharmacology and Molecular Docking Analyses on Lianhua Qingwen Capsule Indicate Akt1 is a Potential Target to Treat and Prevent COVID-19. Cell Proliferation, 53, e12949. [Google Scholar] [CrossRef] [PubMed]
[14] 刘雪. EP300在食管鳞癌发生发展中的作用和机制[D]: [硕士学位论文]. 太原: 山西医科大学, 2021.
[15] Tao, J., Zhang, M., Wen, Z., et al. (2018) Inhibition of EP300 and DDR1 Synergistically Alleviates Pulmonary Fibrosis in Vitro and in Vivo. Biomedicine & Pharmacotherapy, 106, 1727-1733. [Google Scholar] [CrossRef] [PubMed]
[16] Wang, X., Ren, R., Xu, Z., et al. (2021) Tirbanibulin Atte-nuates Pulmonary Fibrosis by Modulating Src/STAT3 Signaling. Frontiers in Pharmacology, 12, Article 693906. [Google Scholar] [CrossRef] [PubMed]
[17] Hao, X., Jin, Y., Zhang, Y., et al. (2023) Inhibition of Oncogenic Src Ameliorates Silica-Induced Pulmonary Fibrosis via PI3K/AKT Pathway. International Journal of Molecular Sciences, 24, Article 774. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, Z., Li, X., Chen, H., et al. (2021) Resveratrol Alleviates Bleomycin-Induced Pulmonary Fibrosis via Suppressing HIF-1α and NF-κB Expression. Aging (Albany NY), 13, 4605-4616. [Google Scholar] [CrossRef] [PubMed]
[19] Montero, P., Milara, J., Roger, I., et al. (2021) Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. International Journal of Molecular Sciences, 22, Article 6211. [Google Scholar] [CrossRef] [PubMed]
[20] Liu, J., Wang, F. and Luo, F. (2023) The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms. Biomolecules, 13, Article 119. [Google Scholar] [CrossRef] [PubMed]
[21] Mohamad, E.A., Mohamed, Z.N., Hussein, M.A., et al. (2022) GANE can Improve Lung Fibrosis by Reducing Inflammation via Promoting p38MAPK/TGF-β1/NF-κB Signaling Pathway Downregulation. ACS Omega, 7, 3109-3120. [Google Scholar] [CrossRef] [PubMed]
[22] Machahua, C., Montes-Worboys, A., Llatjos, R., et al. (2016) Increased AGE-RAGE Ratio in Idiopathic Pulmonary Fibrosis. Respiratory Research, 17, Article No.144. [Google Scholar] [CrossRef] [PubMed]
[23] Huang, W.J. and Tang, X.X. (2021) Virus Infection Induced Pulmonary Fibrosis. Journal of Translational Medicine, 19, Article No.496. [Google Scholar] [CrossRef] [PubMed]